Glucose Monitoring Cgm Systems Articles & Analysis
14 news found
Alertgy, the biotech startup that’s in the race to be the first company to develop an entirely non-invasive glucose monitoring system is proud to welcome a new hire in the Engineering Department: Benjamin Freer joins Alertgy as Director of Engineering/Principal Sensor Engineer. “By far, the most exciting aspect of being on the Alertgy team is the opportunity to see a dream of mine ...
ByAlertgy
Alertgy is excited to announce that we have moved to a new facility! We are still in the process of organizing our new headquarters, but we wanted to share with you our newly expanded capabilities and our progress thus far. Alertgy is also pleased to announce that it has been awarded a Developers Agreement between Alertgy Inc. and SEMI – Flextech. SEMI is the global industry association ...
ByAlertgy
Key Research Survey Findings: 52 percent of healthcare providers agreed motivation is a major barrier to patients adhering to blood glucose monitoring compared to only 10 percent of people with diabetes who agreed motivation is a major barrier. ...
ByLifeScan
LifeScan, a world leader in blood glucose monitoring and digital health technology, is committed to supporting resources that help promote diabetes education and improved health management, including our most recent sponsorship of The Diabetes Way website, offering a straight-forward educational resource – even for those questions you were afraid to ask. Along with educational content ...
ByLifeScan
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings to Creative ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2021. Recent Highlights & Accomplishments: ...
(NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March ...
Food and Drug Administration (FDA) of the next-generation Eversense® E3 continuous glucose monitoring (CGM) System. Ascensia plans to make the E3 sensor, which can be used for up to six months, available to patients in the U.S. during the second quarter of 2022. ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the approval of the next-generation Eversense® E3 CGM System by the Food and Drug ...
(NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates. Operational and Financial Updates Substantive review with the FDA for the ...
(NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating ...
“We are delighted to have Kim on the team”, said Laura Piccinini CEO of RMI. “He brings tremendous wisdom and experience building successful medical device companies.” Mr. Blickenstaff has served as the Chairman of the board of directors of Tandem Diabetes ($5.23 billion market cap) since March 2020. Mr. Blickenstaff previously served as Executive Chairman of the board ...
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 16-20, 2019 in Barcelona. The company recently undertook research to determine ...